|
Group-A
(N=62)
|
Group-P
(N=49)
|
Group-A+P
(N=29)
|
Total
(N=140)
|
P
|
Immunomodulation-related treatments |
|
|
|
|
|
Proglobulin, n (%) |
10 (16.1%) |
11 (22.4%) |
12 (41.4%) |
33
(23.6%) |
0.030 |
Monoclonal antibodies, n (%) |
6 (9.7%) |
1 (2%) |
1 (3.4%) |
8
(5.7%) |
0.179 |
Intravenous hormone use, n (%) |
23 (37.1%) |
31 (63.3%) |
22
(75.9%) |
76 (54.3%) |
0.001 |
Immunosuppressant adjustment |
|
|
|
|
|
CNI reduction, n (%) |
28 (45.2%) |
48 (98.0%) |
26 (96.3%) |
102
(73.9%) |
0.000 |
MMF reduction, n (%) |
56 (90.3%) |
46 (93.9%) |
28 (96.5%) |
130
(92.9%) |
0.509 |
CNI deactivation, n (%) |
16 (25.8%) |
47 (95.9%) |
27 (93.1%) |
90
(64.3%) |
0.000 |
MMF deactivation, n (%) |
53 (85.5%) |
38 (77.5%) |
27 (93.1%) |
118
(84.3%) |
0.178 |
CNI and MMF are both deactivated, n (%) |
18 (29.0%) |
36 (73.5%) |
24 (82.8%) |
78 (55.7%) |
0.000 |
Number of days off immunosuppressive drugs,median (IQR) |
7.0 (6.0,9.5) |
7.0 (6.0,9.5) |
8.5 (7.0,14.0) |
7.0 (6.0,10.0) |
0.071 |